Expression and Significance of LncRNA MEG3 in Hepatocellular Carcinoma
HE Hai-tao, XU Yu, WEI Zhi-li, et al
Department of General Surgery,No.1 Hepatobiliary,The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xixian New District Shaanxi 712000
Abstract：【Objective】 To investigate the expression and value of LncRNA MEG3 in hepatocellular carcinoma (HCC). 【Methods】 A total of 78 patients who were diagnosed with HCC and underwent surgical treatment in our hospital were included in this study. The liver cancer tissues and adjacent normal tissues were collected during operation. At the same time period,78 patients who underwent surgical treatment of "hepatic hemangioma" in our department were enrolled and the intraoperative specimens of them were collected. RT-PCR was used to detect the expression level of LncRNA MEG3 in all subjects and the difference of LncRNA MEG3 levels was compared among different groups. The value of LncRNA MEG3 for diagnosis of HCC was analyzed and the correlation of LncRNA MEG3 with clinical pathological of HCC and alpha fetoprotein (AFP) was studied as well. 【Results】 The expression level of LncRNA MEG3 in HCC tissues was 0.43±0.16,which was lower than that of adjacent normal tissues(1.18±0.35) and hepatic hemangioma(1.21±0.27)(P<0.05).The area under the value curve (AUC)(95%CI) of LncRNA MEG3 for the diagnosis of HCC was 0.85(0.80-0.91),and the best diagnostic cutoff value was 0.91,the sensitivity was 89% and the specificity was 76%.LncRNA MEG3 had a linear positive correlation with AFP (r=0.632,P=0.030).The low expression of LncRNA MEG3 had a correlation with HCC clinical stage,differentiation and distant metastasis of liver cancer (χ2 were 3.93,6.59 and 4.43,respectively,P<0.05). 【Conclusion】 LncRNA MEG3 has low expression in HCC,and it is closely related to the clinicopathology of HCC,which can be severed as a potential target for diagnosis and treatment of HCC.
[1] SCHMITT A M,CHANG H. Long Noncoding RNAs:at the intersection of cancer and chromatin biology[J].Cold Spring Harb Perspect Med,2017,7(7):264-292.
[2] ZHOU Y L,ZHANG X,KLIBANSKI A. MEG3 noncoding:A tumor suppressor[J].J Mol Endocrinol,2012,48(3):R45-R53.
[3] HE Y Q,LUO Y H,LIANG B Y,et al. Potential applications of MEG3 in cancer diagnosis and prognosis[J].Oncotarget,2017,8(42):73282-73295.
[4] GOLDBERG D S,VALDERRAMA A,KAMALAKAR R,et al. Hepatocellular carcinoma surveillance among cirrhotic patients with commercial health insurance[J].J Clin Gastroenterol,2016,50(3):258-265.
[5] WEI G H,WANG X.lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway[J].Eur Rev Med Pharmacol Sci,2017,21(17):3850-3856.
[6] 葛均波,徐永健,梅长林,等. 内科学[M].8版.北京:人民卫生出版社,2015:429-433.
[7] 国际肝胆胰协会中国分会肝血管瘤专业委员会. 肝血管瘤诊断和治疗多学科专家共识(2019版)[J].中华消化外科杂志,2019,18(8):705-710.
[8] 黄颖,史耀琪,胡佳明,等. 姜黄素调控LncRNA MEG3/miR-21/PTEN通路促HPV阳性宫颈癌细胞凋亡[J].温州医科大学学报,2022,52(2):115-120.
[9] LI L X,SHANG J,ZHANG Y P,et al. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis[J].Oncol Rep,2017,38(3):1383-1392.
[10] LU K H,LI W,LIU X H,et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression[J].BMC Cancer,2013,13:461.
[11] WANG P J,REN Z Q,SUN P Y. Overexpression of the long non-coding RNA MEG3 impairs in vitroglioma cell proliferation[J].J Cell Biochem,2012,113(6):1868-1874.
[12] MA L,WANG F,DU C,et al.Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer[J].Oncol Rep,2018,39(3):1132-1140.
2023, Vol. 40 
